AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31309232
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg/kg Genistein)
Trial: 17972459
Drug: Magnesium (Mg)
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (Mg)
Trial: 17972459
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between S100beta and Mg
Trial: 9440565
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol (FM), 24 microg bid, and placebo tablets (PL)
Trial: 9440565
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol (FM), 24 microg bid, and oral prednisolone (PRED), 15 mg daily
Trial: 29424248
Drug: Pemetrexed maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed maintenance therapy
Trial: 25956613
Drug: Fenofibrate 300
RxNorm normalized name: fenofibrate 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 300 mg daily plus pentoxifylline 1200 mg/day in three divided doses for 24 weeks
Trial: 22543064
Drug: Volume-controlled ventilation
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volume-controlled ventilation (VCV) with tidal volume (Vt) of 8 mL•kg(‐1) and PEEP of 0 cm H(2)O
Trial: 22543064
Drug: Pressure-controlled ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-controlled ventilation (PCV) with tidal volume (Vt) of 8 mL•kg(‐1) and PEEP of 0 cm H(2)O
Trial: 16736620
Drug: Three-point relief-tension
RxNorm normalized name: Point Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-point relief-tension suspension technique (Group A)
Trial: 11083648
Drug: Oxacillin-dicloxacillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxacillin-dicloxacillin (500 mg orally every 6 h)
Trial: 11376633
Drug: Gemfibrozil (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (900 mg once daily)
Trial: 1298571
Drug: Shower-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shower-based oral hygiene system (SBOHS)
Trial: 2420603
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cisplatin, vinblastine and bleomycin followed by intravenous cyclophosphamide
Trial: 2420603
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (consolidation regimen)
Trial: 26679830
Drug: AUD$30 cash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUD$30 cash following receipt of doses two and three (incentive condition)
Trial: 24632109
Drug: family‐based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: family‐based treatment
Trial: 19934404
Drug: Selective COX‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective COX‐2 inhibitor
Trial: 23338252
Drug: Steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroidal anti-inflammatory drug
Trial: 12419715
Drug: Three minutes
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three minutes of supramaximal stimulation (0.1 Hz, 20 mA) before mivacurium 0.2 mg.kg(‐1)
Trial: 12419715
Drug: Ten minutes
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten minutes of supramaximal stimulation (0.1 Hz, 20 mA) before mivacurium 0.2 mg.kg(‐1)
Trial: 11153926
Drug: Chelating agent
RxNorm normalized name: Chelating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelating agent (DMPS)
Trial: 4033539
Drug: Prednisone (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1.2 mg/kg/day for 70 days)
Trial: 4033539
Drug: Alkylating agent
RxNorm normalized name: Alkylating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkylating agent alone
Trial: 27676085
Drug: Oral extended-release
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral extended-release calcifediol (30 or 60 µg) once daily at bedtime for 26 weeks
Trial: 28685934
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg/d for 6 weeks
Trial: 24990161
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) combined with rabeprazole (RPZ) 10 mg/q.d. for 8 weeks
Trial: 22883036
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion (loading dose 100 µg/kg followed by continuous infusion 10 µg/(kg·h) for 70.05 ± 29.05 h)
Trial: 3318543
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion
Trial: 19001742
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose infusion (control group)
Trial: 12114036
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin daily
Trial: 10786531
Drug: Education programme
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education programme on how to use and take care of a PIV; details on dosage and duration not available.
Trial: 10786531
Drug: Current routines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current routines followed by nurses in the control group; details on dosage and duration not available.
Trial: 1972313
Drug: Aldactazine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldactazine alone (altizide + spironolactone, 2 tablets per day)
Trial: 1972313
Drug: Aldactazine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldactazine plus a conventional antihypertensive agent (1 or 2 tablets per day)
Trial: 31865815
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (control)
Trial: 25517202
Drug: Caffeine chewing
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine chewing gum (3-4 mg · kg(‐1))
Trial: 10922420
Drug: Omeprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (80 mg bolus intravenous injection followed by 8 mg per hour infusion for 72 hours, then 20 mg orally per day for 8 weeks)
Trial: 10922420
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same treatment protocol as omeprazole but without the active drug)
Trial: 9314091
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg daily for 7 days
Trial: 9314091
Drug: Propafenone 300
RxNorm normalized name: propafenone 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 300 mg per os twice a day
Trial: 7870968
Drug: Intravenous meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine (0.25 mg/kg)
Trial: 7870968
Drug: Intravenous meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine (0.5 mg/kg)
Trial: 7870968
Drug: Intravenous meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine (1.0 mg/kg)
Trial: 31992589
Drug: Cabozantinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (60 mg once daily)
Trial: 20065174
Drug: Preoperative CRT
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative CRT with capecitabine, oxaliplatin, and concurrent radiation followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)
Trial: 6263072
Drug: Oat-bran diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat-bran diet (100 g of oat bran)
Trial: 29605574
Drug: Cinnamon supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon supplementation (500 mg capsules twice daily for 3 months)
Trial: 29605574
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg capsules twice daily for 3 months)
Trial: 12616104
Drug: IL-2 +
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 + GM-CSF (125 mcg/m)
Trial: 12616104
Drug: IL-2 +
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 + GM-CSF (250 mcg/m)
Trial: 10795791
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (4 x 5 g creatine + 1 g glucose x d(‐1), N = 11)
Trial: 10795791
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 x 6 g glucose x d(‐1), N = 12)
Trial: 8677576
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 400 mg fleroxacin
Trial: 8677576
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous (IV) dose of 400 mg fleroxacin
Trial: 8677576
Drug: Extended regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended regimen of initial 400 mg IV dose followed by oral therapy (400 mg/day or 200 mg/day for specific patients)
Trial: 8677576
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antibiotic prophylaxis mentioned)
Trial: 2497545
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ASA
Trial: 195201
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g butylbiguanide and 1.5 g clofibrate/day
Trial: 30768860
Drug: Filgotinib maleate
RxNorm normalized name: filgotinib maleate
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Filgotinib maleate tablets (100 mg and 200 mg)
Trial: 30768860
Drug: Filgotinib maleate
RxNorm normalized name: filgotinib maleate
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Filgotinib maleate tablets with food (high-fat meal)
Trial: 30768860
Drug: Filgotinib maleate
RxNorm normalized name: filgotinib maleate
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Filgotinib maleate tablets with omeprazole
Trial: 30768860
Drug: Filgotinib maleate
RxNorm normalized name: filgotinib maleate
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Filgotinib maleate tablets with famotidine
Trial: 30768860
Drug: Reference tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference tablet (filgotinib hydrochloride)
Trial: 28712478
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (EMLA cream)
Trial: 21368587
Drug: Pregabalin 450
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 450 mg
Trial: 12798785
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg NaCl
Trial: 12798785
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg NaCl
Trial: 12798785
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg NaCl
Trial: 19234720
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of antibodies against BCL-2 in patients' sera
Trial: 19234720
Drug: Anti-BCL-2 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-BCL-2 antibodies
Trial: 18184536
Drug: Meracilina/Pen‐Ve‐Oral 500,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meracilina/Pen‐Ve‐Oral 500,000 UI
Trial: 15369506
Drug: REMUNE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REMUNE therapy every 12 weeks for 132 weeks
Trial: 15369506
Drug: REMUNE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REMUNE therapy
Trial: 15369506
Drug: REMUNE monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REMUNE monotherapy or REMUNE plus antiretrovirals (ARTs)
Trial: 9104523
Drug: 0.2 mg.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg.kg-1 propofol
Trial: 8251277
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with background infusion of morphine
Trial: 3535990
Drug: Radiotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy followed by chemotherapy
Trial: 8584072
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASS) at dosages of > or = 975 mg per day
Trial: 8487136
Drug: EMLA (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA (topical anesthetic)
Trial: 22187234
Drug: Non-therapy control
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-therapy control
Trial: 30006024
Drug: Hepatitis C-Alcohol
RxNorm normalized name: hepatitis C virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention
Trial: 30006024
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (TAU)
Trial: 24816809
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus heparin
Trial: 19875761
Drug: Anti‐CD20 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐CD20 monoclonal antibody therapy
Trial: 19875761
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (anthracycline‐based)
Trial: 15797671
Drug: Inulin-fortified beverages
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin-fortified beverages (13 g/d)
Trial: 12019107
Drug: Stavudine (d4T)
RxNorm normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine (d4T) at 40 mg twice daily, 3TC at 150 mg twice daily, and indinavir at 800 mg every 8 h
Trial: 8120917
Drug: GnRHA-based contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHA-based contraceptive regimen (7.5 mg leuprolide acetate depot every 28 days, 0.625 mg conjugated estrogen for 6 days each week, 10 mg medroxyprogesterone acetate for 13 days every fourth cycle)
Trial: 2683658
Drug: 0.4 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 ml/kg of iohexol
Trial: 2683658
Drug: 0.8 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 ml/kg of iohexol
Trial: 1098887
Drug: Slow-release aminophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release aminophylline (350 mg, released over eight hours)
Trial: 12379887
Drug: G-CSF treatment
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF treatment started on day 9 post transplant
Trial: 2757327
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories of PDRN (10g preparation)
Trial: 29331656
Drug: Optimal turning
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal turning practices influenced by real-time data from a wearable patient sensor (treatment group, n=659)
Trial: 27481621
Drug: Restrictive threshold
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive threshold (transfuse if haemoglobin <7.5 g/dL)
Trial: 27481621
Drug: Liberal threshold
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal threshold (transfuse if haemoglobin <9 g/dL)
Trial: 12730050
Drug: 6R‐5,6,7,8‐tetrahydro‐l‐biopterin dihydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6R‐5,6,7,8‐tetrahydro‐l‐biopterin dihydrochloride (6R‐BH4; n = 10)
Trial: 12730050
Drug: 6S‐5,6,7,8‐tetrahydro‐l‐biopterin sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6S‐5,6,7,8‐tetrahydro‐l‐biopterin sulfate (6S‐BH4; n = 10)
Trial: 8633669
Drug: oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral contraceptive (50 microg ethinyl estradiol and 250 microg levonogestrel)
Trial: 23009244
Drug: Home-based management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based management of malaria (HMM) using rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT)
Trial: 7539184
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (alpha 1 blockade + androgen suppression)
Trial: 1899776
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of recombinant tissue-type plasminogen activator (rt-PA)
Trial: 27261222
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) after a withdrawal bleed induced by Medroxyprogesterone Acetate (MPA) 10 mg daily for 10 days
Trial: 27261222
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) without a preceding withdrawal bleed
Trial: 21258125
Drug: Thyroxine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine (50 µg daily, increased as necessary)
Trial: 8493493
Drug: Glucose-insulin-potassium infusion
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium infusion (0.5 g glucose, 1.35 IU insulin, 0.25 mmol/kg b.w/hour)
Trial: 1637215
Drug: Glucose-insulin-potassium infusion
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium infusion
Trial: 8493493
Drug: Glucose-insulin-potassium infusion
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium infusion and Control group
Trial: 3121928
Drug: Naloxone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (4 mg bolus followed by 2 mg/h infusion for 4 h)
Trial: 24347426
Drug: Estrogen administration
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen administration
Trial: 8638453
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg intravenous dehydroepiandrosterone sulfate (DHAS) in 20 ml of 5% dextrose
Trial: 8638453
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 5% dextrose (control)
Trial: 8638453
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg intravenous dehydroepiandrosterone sulfate (DHAS)
Trial: 1365017
Drug: G‐CSF in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF in patients receiving positively selected marrow
Trial: 31721670
Drug: Negative wound
RxNorm normalized name: Microcyn Negative Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative wound pressure therapy (NPWT)
Trial: 20158620
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (2 microg x kg(‐1)) + caudal 0.25% levobupivacaine
Trial: 16273784
Drug: Disease modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease modifying drugs and biologic agents
Trial: 371056
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg salbutamol solution
Trial: 3291074
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ivermectin (150 micrograms/kg)
Trial: 1867345
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of ivermectin (150 micrograms/kg) at 6-month intervals
Trial: 6354826
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (800 mg/day)
Trial: 29728334
Drug: Alprostadil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil (2 μg by intracoronary infusion)
Trial: 29728334
Drug: Nitroglycerin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (200 μg)
Trial: 26556733
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid infusion
Trial: 23788684
Drug: Denosumab injection
RxNorm normalized name: denosumab Injection
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab injection